Pharmacogenetics of anesthetic and analgesic agents

Anesthesiology

Volumn 102, Issue 3, 2005, Pages 663-671

  Palmer, Stephen N ^b   Giesecke, N Martin ^b   Body, Simon C ^b   Shernan, Stanton K ^b   Fox, Amanda A ^b   Collard, Charles D ^a  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ANALGESIC AGENT; ANESTHETIC AGENT; CELECOXIB; CODEINE; DIAZEPAM; DICLOFENAC; FENTANYL; FLURBIPROFEN; HALOTHANE; IBUPROFEN; ISOFLURANE; METHADONE; MIDAZOLAM; MIVACURIUM; MORPHINE; MORPHINE 6 GLUCURONIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; SUFENTANIL; SUXAMETHONIUM; TRAMADOL;

ANAPHYLAXIS; CONFERENCE PAPER; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; GENETIC ASSOCIATION; HEPATITIS; HUMAN; LIVER TOXICITY; MALIGNANT HYPERTHERMIA; MOLECULAR BIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; SOMNOLENCE;

ANALGESICS; ANESTHETICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; NARCOTICS; NEUROMUSCULAR BLOCKING AGENTS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 14644411065     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200503000-00028     Document Type: Conference Paper

References (77)

1. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998; 279: 1200-5
2. Rodriguez-Monguio R, Otero MJ, Rovira J: Assessing the economic impact of adverse drug effects. Pharmacoeconomics 2003; 21: 623-50
3. Bukaveckas BL, Valdes R Jr, Linder MW: Pharmacogenetics as related to the practice of cardiothoracic and vascular anesthesia. J Cardiothorac Vasc Anesth 2004; 18: 353-65
4. Body SC, Shernan SK: Implications of pharmacogenetics for the practice of anesthesiology, Advances in Anesthesia. Edited by Lake CL, Johnson JO, McLoughlin TM. Philadelphia, Mosby, 2003, pp 269-96
5. Iohom G, FitzGerald D, Cunningham AJ: Principles of pharmacogenetics: Implications for the anaesthetist. Br J Anaesth 2004; 93:440-50
6. Ziegeler S, Tsusaki BE, Collard CD: Influence of genotype on perioperative risk and outcome. ANESTHESIOLOGY 2003; 99:212-9
7. Hoehe MR, Timmermann B, Lehrach H: Human inter-individual DNA sequence variation in candidate genes, drug targets, the importance of haplotypes and pharmacogenomics. Curr Pharm Biotechnol 2003; 4:351-78
8. Jensen FS, Viby-Mogensen J: Plasma cholinesterase and abnormal reaction to succinylcholine: Twenty years' experience with the Danish Cholinesterase Research Unit. Acta Anaesthesiol Scand 1995; 39:150-6
9. Ostergaard D, Jensen FS, Skovgaard LT, Viby-Mogensen J: Dose-response relationship for mivacurium in patients with phenotypically abnormal plasma cholinesterase activity. Acta Anaesthesiol Scand 1995; 39:1016-8
10. Cerf C, Mesguish M, Gabriel I, Amselem S, Duvaldestin P: Screening patients with prolonged neuromuscular blockade after succinylcholine and mi-vacurium. Anesth Analg 2002; 94:461-6
11. Qin XP, Xie HG, Wang W, He N, Huang SL, Xu ZH, Ou-Yang DS, Wang YJ, Zhou HH: Effect of the gene dosage of CγP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther 1999; 66:642-6
12. Kosuge K, Jun Y, Watanabe H, Kimura M, Nishimoto M, Ishizaki T, Ohashi K: Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Drug Metab Dispos 2001; 29:1284-9
13. Bertilsson L: Geographical/interracial differences in polymorphic drug oxidation: Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29:192-209
14. Shih PS, Huang JD: Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 2002; 30:1491-6
15. Gob BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Schuetz E, Lim R, Lim HL, Ong AB, Lee HS: Explaining interindividual variability of docetaxel pharmacokineties and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20:3683-90
16. Wandel C, Witte JS, Hall JM, Stein CM. Wood AJ, Wilkinson GR: CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4* IB5'-promoter region polymorphism. Clin Pharmacol Ther 2000; 68:82-91
17. Girard T, Urwyler A, Censier K. Mueller CR, Zorzato F. Treves S: Genotype-phenotype comparison of the Swiss malignant hyperthermia population. Hum Mutat 2001; 18:357-8
18. Stewart SL, Hogan K, Rosenberg H, Fletcher JE: Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia. Clin Genet 2001; 59:178-84
19. Fagerlund TH, Braaten O: No pain relief from codeine? An introduction to pharmacogenomics. Acta Anaesthesiol Scand 2001; 45:140-9
20. Robinson RL, Brooks C. Brown SL, Ellis FR, Halsall PJ, Quinnell RJ, Shaw MA, Hopkins PM: RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes. Hum Mutat 2002; 20:88-97
21. Guis S, Figarella-Branger D, Monnier N, Bendahan D, Kozak-Ribbens G, Mattel JP, Lunardi J, Cozzone PJ, Pellissier JF: Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization. Arch Neurol 2004; 61:106-13
22. Sambuughin N, Sei Y, Gallagher KL, Wyre HW, Madsen D, Nelson TE, Fletcher JE, Rosenberg H, Muldoon SM: North American malignant hyperthermia population: Screening of the ryanodine receptor gene and identification of novel mutations. ANESTHESIOLOGY 2001; 95:594-9
23. Barone V, Massa O, Intravaia E, Bracco A, Di Martino A, Tegazzin V, Cozzolino S, Sorrentino V: Mutation screening of the RYR1 gene and identification of two novel mutations in Italian malignant hyperthermia families. J Med Genet 1999; 36:115-8
24. Rueffert H, Olthoff D, Deutlich C, Meinecke CD, Froster UG: Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations. Acta Anaesthesiol Scand 2002; 46:692-8
25. Rueffert H, Olthoff D, Deutrich C, Thamm B, Froster UG: Homozygous and heterozygous Arg614Cys mutations (1840C->T) in the ryanodine receptor gene co-segregate with malignant hyperthermia susceptibility in a German family. Br J Anaesth 2001; 87:240-5
26. Manning BM, Quane KA, Ording H, Urwyler A, Tegazzin V, Lehane M, O'Halloran J, Hartung E, Giblin LM, Lynch PJ, Vaughan P, Censier K, Bendixen D, Comi G, Heytens L, Monsieurs K, Fagerlund T, Wolz W, Heffron JJ, Muller CR, McCarthy TV: Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation. Am J Hum Genet 1998; 62:599-609
27. Kharasch ED, Hankins D, Mautz D, Thummel KE: Identification of the enzyme responsible for oxidative halothane metabolism: Implications for prevention of halothane hepatitis. Lancet 1996; 347:1367-71
28. Eliasson E, Gardner I, Hume-Smith H, de W, I, Beaune P, Kenna JG: Interindividual variability in P450-dependent generation of neoantigens in halothane hepatitis. Chem Biol Interact 1998; 116:123-41
29. Larrey D, Pageaux GP: Genetic predisposition to drug-induced hepatotoxicity. J Hepatol 1997; 26(suppl 2):12-21
30. Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T, Gonzalez FJ: Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 1995; 5:143-50
31. McCarver DG, Byun R, Mines RN, Hichme M, Wegenek W: A genetic polymorphism in the regulatory sequences of human CYP2E1: Association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol Appl Pharmacol 1998; 152:276-81
32. Marchand LL, Wilkinson GR, Wilkens LR: Genetic and dietary predictors of CYP2E1 activity: A phenotyping study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiol Biomarkers Prev 1999; 8:495-500
33. Campagna JA, Miller KW, Forman SA: Mechanisms of actions of inhaled anesthetics. N Engl J Med 2003; 348:2110-24
34. Mueller JL, Ellenberger EA, Vaughn LK, Belknap JK, Quock RM: Detection and mapping of quantitative trait loci that determine responsiveness of mice to nitrous oxide antinociception. Neuroscience 2004; 123:743-9
35. Xing Y, Sonner JM, Eger EI, Cascio M, Sessler DI: Mice with a melanocortin 1 receptor mutation have a slightly greater minimum alveolar concentration than control mice. ANESTHESIOLOGY 2004; 101:544-6
36. Sonner JM, Gong D, Eger EI: Naturally occurring variability in anesthetic potency among inbred mouse strains. Anesth Analg 2000; 91:720-6
37. Selzer RR, Rosenblatt DS, Laxova R, Hogan K: Adverse effect of nitrous oxide in a child with 5,10-methylenetetrahydrofolate reductase deficiency. N Engl J Med 2003; 349:45-50
38. Erbe RW, Salis RJ: Severe methylenetetrahydrofolate reductase deficiency, methionine synthase, and nitrous oxide: A cautionary tale. N Engl J Med 2003; 349:5-6
39. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L: Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: Possible implications for opiate addiction. Proc Natl Acad Sci USA 1998; 95:9608-13
40. Lotsch J, Zimmermann M, Darimont J, Marx C, Dudziak R, Skarke C, Geisslinger G: Does the A118G polymorphism at the μ-opioid receptor gene protect against morphine-6-glucuronide toxicity? ANESTHESIOLOGY 2002; 97:814-9
41. Skarke C, Darimont J, Schmidt H, Geisslinger G, Lotsch J: Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 2003; 73:107-21
42. Uhl GR, Sora I, Wang Z: The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci U S A 1999; 96:7752-5
43. Sawyer MB, Innocenti F, Das S, Cheng C, Ramirez J, Pantle-Fisher FH, Wright C, Badner J, Pei D, Boyett JM, Cook E Jr, Ratain MJ: A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 2003; 73:566-74
44. Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH: Codeine and morphine in extensive and poor metabolizers of sparteine: Pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996; 51:289-95
45. Ingelman-Sundberg M: Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: Evolutionary, toxicological, and clinical pharmacological aspects. Drug Metab Rev 1999; 31:449-59
46. Eckhardt K, Li S, Ammon S, Schanzle G, Mikus G, Eichelbaum M: Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998; 76:27-33
47. Eichelbaum M, Kroemer HK, Fromm MF: Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs. Adv Drug Deliv Rev 1997; 27:171-99
48. Bachs L, Skurtveit S, Morland J: Codeine and clinical impairment in samples in which morphine is not detected. Eur J Clin Pharmacol 2003; 58:785-9
49. Levo A, Koski A, Ojanpera I, Vuori E, Sajahtila A: Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood. Forensic Sci Int 2003; 135:9-15
50. Stamer UM, Lehnen K, Hothker F, Bayerer B, Wolf S, Hoeft A, Stuber F: Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003; 105:231-8
51. Eap CB, Broly F, Mino A, Hammig R, Deglon JJ, Uehlinger C, Meili D, Chevalley AF, Bertschy G, Zullino D, Kosel M, Preisig M, Baumann P: Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol 2001; 21:229-34
52. Shiran MR, Chowdry J, Rostami-Hodjegan A, Ellis SW, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT: A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol 2003; 56:220-4
53. Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P, Menez JF: Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996; 9:365-73
54. Foster DJ, Somogyi AA, Bochner F: Methadone N-demethylation in human liver microsomes: Lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 1999; 47:403-12
55. Guitton J, Buronfosse T, Desage M, Lepape A, Brazier JL, Beaune P: Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil. Biochem Pharmacol 1997; 53:1613-9
56. Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle A, Cox K: The role of cytochrome P450 3A4 in alfentanil clearance: Implications for interindividual variability in disposition and perioperative drug interactions. ANESTHESIOLOGY 1997; 87:36-50
57. Kest B, Sarton E, Dahan A: Gender differences in opioid-mediated analgesia: Animal and human studies. ANESTHESIOLOGY 2000; 93:539-47
58. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, Koeppe RA, Stohler CS, Goldman D: COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003; 299:1240-3
59. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, Taskinen J: Kinetics of human soluble and membrane-bound catechol O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995; 34:4202-10
60. Vandenbergh DJ, Rodriguez LA, Miller IT, Uhl GR, Lachman HM. High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. Am J Med Genet 1997; 74:439-42
61. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR: Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001; 98:6917-22
62. LaForge KS, Yuferov V, Kreek MJ: Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur J Pharmacol 2000; 410:249-68
63. Kreek MJ, Nielsen DA, LaForge KS: Genes associated with addiction: Alcoholism, opiate, and cocaine addiction. Neuromolecular Med 2004; 5:85-108
64. Sandberg M, Yasar U, Stromberg P, Hoog JO, Eliasson E: Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol 2002; 54:423-9
65. Kirchheiner J, Stormer E, Meisel C, Steinbach N, Roots I, Brockmoller J: Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics 2003; 13:473-80
66. Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, Dickmann LJ: Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: Effect on atypical kinetic metabolism profiles. Drug Metab Dispos 2002; 30:385-90
67. Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ, Rose MJ, Gelmann A, Greenberg HE, De L, I, Van Hecken A, De Schepper PJ, Ebel DL, Schwanz JI, Rodrigues AD: In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: Correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 2001; 11:223-35
68. Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I, Brockmoller J: Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther 2002; 72:62-75
69. Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA: Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol 2003; 43:84-91
70. Yasar U, Eliasson E, Forslund-Bergengren C, Tybring G, Gadd M, Sjoqvist F, Dahl ML: The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 2001; 57:729-35
71. Brenner SS, Herrlinger C, Dilger K, Murdter TE, Hofmann U, Marx C, Klotz U: Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin Pharmacokinet 2003; 42:283-92
72. Aithal GP, Day CP, Leathart JB, Daly AK: Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000; 10:511-8
73. Ueshima Y, Tsutsumi M, Takase S, Matsuda Y, Kawahara H: Acetaminophen metabolism in patients with different cytochrome P-4502E1 genotypes. Alcohol Clin Exp Res 1996; 20:25A-8A
74. Bernal W, Donaldson P, Underbill J, Wendon J, Williams R: Tumor necrosis factor genomic polymorphism and outcome of acetaminophen (paracetamol)-induced acute liver failure. J Hepatol 1998; 29:53-9
75. Quiralte J, Sanchez-Garcia F, Torres MJ, Blanco C, Castillo R, Ortega N, de Castro FR, Perez-Aciego P, Carrillo T: Association of HLA-DR11 with the anaphylactoid reaction caused by nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol 1999; 103:685-9
76. Pritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, Bell DA: Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther 2001; 299:468-76
77. Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, Pini B, Ursi S, Vitullo G, Averna M, Area M, Montali A, Campagna F, Ucchino S, Spigonardo F, Taddei S, Virdis A, Ciabattoni G, Notarbartolo A, Cuccurullo F, Mezzetti A: A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 2004; 291:2221-8